Showing results (991-1000 of 3,473) with videos related to

Sort By:
Pageof 348
Clinical Pharmacokinetics|April 5, 2011
Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humansSamanta Yubero-Lahoz, Ricardo Pardo, Magí Farré, et al.
Clinical Pharmacokinetics|April 5, 2011
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modellingHannah M Jones, Iain B Gardner, Wendy T Collard, et al.
Clinical Pharmacokinetics|May 11, 2011
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Robert P Nelson, et al.
Clinical Pharmacokinetics|June 10, 2011
Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disordersVenkatesh Pilla Reddy, Magdalena Kozielska, Martin Johnson, et al.
Clinical Pharmacokinetics|June 10, 2011
Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizuresMarcel P H van den Broek, Alwin D R Huitema, Johan G C van Hasselt, et al.
Clinical Pharmacokinetics|June 10, 2011
Asenapine pharmacokinetics in hepatic and renal impairmentPierre Peeters, Howard Bockbrader, Edwin Spaans, et al.
Clinical Pharmacokinetics|September 11, 2015
Drug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirSivi Ouwerkerk-Mahadevan, Jan Snoeys, Monika Peeters, et al.
Clinical Pharmacokinetics|September 6, 2015
Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling PredictionsChristophe Boetsch, Neil Parrott, Stephen Fowler, et al.
Clinical Pharmacokinetics|September 6, 2015
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic MalignanciesElodie Odore, François Lokiec, Esteban Cvitkovic, et al.
Clinical Pharmacokinetics|September 23, 2015
Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free MonotherapiesKai Kaarniranta, Kirsi Ikäheimo, Eliisa Mannermaa, et al.
Pageof 348